Molecular Pharmaceutics
[ASAP] Phosphorylated Serine-Modified Polyamidoamine Dendrimer as an Osteoid Surface-Targeting Drug Carrier
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00271
Molecular Pharmaceutics
[ASAP] Multiphase Drug Distribution and Exchange in Oil-in-Water Nanoemulsion Revealed by High-Resolution <sup>19</sup>F qNMR
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00025
Molecular Pharmaceutics
[ASAP] Correction to “Skin Pharmacokinetics of Transdermal Scopolamine: Measurements and Modeling”
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00400
Molecular Pharmaceutics
[ASAP] PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00281
Molecular Pharmaceutics
[ASAP] Optimization of a Liposomal DNase I Formulation with an Extended Circulating Half-Life
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00086
Molecular Pharmaceutics
[ASAP] Preclinical Investigations to Explore the Difference between the Diastereomers [<sup>177</sup>Lu]Lu-SibuDAB and [<sup>177</sup>Lu]Lu-RibuDAB toward Prostate Cancer Therapy
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00994
Molecular Pharmaceutics
[ASAP] Research Progress on Nanoplatforms and Nanotherapeutic Strategies in Treating Glioma
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00856
Molecular Pharmaceutics
[ASAP] Effect of pH on the Surface Layer of Molecular Crystals at the Solid–Liquid Interface
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.2c00087
Molecular Pharmaceutics
[ASAP] Intravenous Administration of Scutellarin Nanoparticles Augments the Protective Effect against Cerebral Ischemia–Reperfusion Injury in Rats
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00942
Molecular Pharmaceutics
[ASAP] Gallium Mesoporphyrin IX-Mediated Photodestruction: A Pharmacological Trojan Horse Strategy To Eliminate Multidrug-Resistant <italic toggle=”yes”>Staphylococcus aureus</italic>
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.1c00993